血液とリンパのジャーナル

The JAK-STAT pathway mediates signals that are involved in hematopoiesis. Aberrant JAK-STAT signaling has been identified in myeloproliferative neoplasm making the pathway a novel therapeutic target for myeloproliferative neoplasms through the application of JAK inhibitors. A major limitation to therapy with the current JAK inhibitors is a lack of selectivity which results in toxicity to patients. It is thought that increasing the selectivity of inhibitors will reduce toxicity observed with JAK inhibition therapy. System biology is a novel technology that holds great potentials for increasing the selectivity of JAK inhibitors. Its Application to drug designing can broaden the spectrum as well as repurpose the available JAK inhibitors for improved clinical outcome and possible cure for myeloproliferative neoplasms. This review presents an overview on the role of system biology in JAK inhibition therapy for myeloproliferative neoplasms.

In Pakistan the disease burden of Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) is quite high, yet there is a lack of scientific evidence regarding the spectrum of BCR-ABL rearrangement variants in CML and ALL. Knowing about BCR-ABL rearrangement is important in determining the prognosis and treatment strategy of disease at the time of diagnosis. This study included a total of 685 patients, out of which there were 644 CML patients and 41 ALL patients, from October 2016-July 2019. From the CML group, 270 patients were reported to have the BCR-ABL1 transcript, from which 50% were males. Whereas in the ALL group, 35 patients were reported to have the BCR-ABL1 transcript out of which 65.7% were males. Proportions of BCR-ABL transcript type differed between the two groups, with b3a2 (63.3%) and b2a2 (34.8%) transcript types having the highest frequency in CML patients, whereas e1a2 (77.1%) and b3a2 (11.3%) transcript types were found to have the highest frequency in ALL patients. Our data shows transcript genotypes in CML and ALL patients in an Asian population, which may be useful to guide the clinical management and assess prognosis. Since the majority of our CML population had the b3a2 transcript, they have a better prognosis and treatment response.

Pharmacokinetics is the investigation of digestion of medications in organic liquids, tissues and excreta. The discoveries of ongoing improvements uncover that Multidrug Obstruction (MDR) adjusted the bioavailability of orally managed drugs through enlistment or restraint. Part of Multi-drug treatment: MDR is a term used to portray the marvel described by the capacity of medication safe tumors to display synchronous protection from various primarily and practically disconnected chemotherapeutic specialists. Various systems have been portrayed to clarify the wonder of MDR in mammalian cells. They have been extensively ordered into cell and non-cell components. Boundaries of pharmacokinetic inconstancy in malignancy patients:

Road traffic accidents are increasing day by day which will result in Spinal cord Injury to the victims. In Spinal cord Injury nervous system is affected which is not re-gene ratable so whatever damage occur its permanent for rest of life. Thoracic spinal cord injury patient have spared Upper extremities and some trunk muscle with use of those and some assistive devices patient can achieve the independence in his life